FORM 4

### **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| OMB A | PP | RO | VAI |
|-------|----|----|-----|
|-------|----|----|-----|

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| purchase or sale of issuer that is inten   | e conditions of Rule |       |  |                   |   |                       |
|--|----------------------|-------|--|-------------------|---|-----------------------|
| Name and Address of Reporting Person*     Ben Yong                                     |                      |       | 2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] | 5. Rela<br>(Check | on(s) to Issuer   |                       |
| (Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE |                      | ` ,   | 3. Date of Earliest Transaction (Month/Day/Year) 05/30/2025                                |                   | Officer (give title below)  | Other (specify below) |
| (Street)<br>NORWOOD  | MA                   | 02062 | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                   | 6. Indiv          | vidual or Joint/Group Filing<br>Form filed by One Repo<br>Form filed by More than | , ,                   |
| (City)   | (State)              | (Zip) |  |                   |   |                       |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| in this or coounty (mounts)                | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |   | 4. Securities Ac<br>Disposed Of (D |               |       | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported<br>Transaction(s) | or Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|---|---|---|------------------------------------|---------------|-------|--|-------------------------------|---|
|  |  |   | Code                                    | v | Amount                             | (A) or<br>(D) | Price | (Instr. 3 and 4)   |                               | (111501. 4)   |
| Common Stock, par value \$0.0001 per share | 05/30/2025                                 |   | A                                       |   | 4,800(1)                           | A             | \$0   | 7,583(2)   | D                             |   |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |            | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (Ir<br>8) |   | Derivative |     | Expiration Date     |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|--|---|------------|---|---------------------------------|---|------------|-----|---------------------|--------------------|--|-------------------------------------|---|--|--|--|
|  |   |            |   | Code                            | v | (A)        | (D) | Date<br>Exercisable | Expiration<br>Date | Title  | Amount<br>or<br>Number of<br>Shares |   | Transaction(s)<br>(Instr. 4)   |  |  |
| Stock options<br>(right to buy)                  | \$7.42  | 05/30/2025 |   | A                               |   | 16,000     |     | (3)                 | 05/30/2035         | Common<br>Stock  | 16,000                              | \$0   | 16,000   | D  |  |

## Explanation of Responses:

- 1. On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value \$0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
- 2. This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.
- 3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

/s/ Meghan Houghton, attorney-infact for Yong Ben

06/02/2025

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.